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SUMMARY 23	  
  Recognition and repair of damaged replication forks is essential to maintain genome 24	  
stability, and is coordinated by the combined action of the Fanconi Anaemia and homologous 25	  
recombination pathways. These pathways are vital to protect stalled replication forks from 26	  
uncontrolled nucleolytic activity, which otherwise causes irreparable genomic damage. Here we 27	  
identify BOD1L as a component of this fork protection pathway, which safeguards genome stability 28	  
after replication stress. Loss of BOD1L confers exquisite cellular sensitivity to replication stress 29	  
and uncontrolled resection of damaged replication forks, due to a failure to stabilise Rad51 at 30	  
these forks. Blocking DNA2-dependent resection, or down regulation of the helicases BLM and 31	  
Fbh1, suppresses both catastrophic fork processing and the accumulation of chromosomal 32	  
damage in BOD1L-deficient cells. Thus, our work implicates BOD1L as a critical regulator of 33	  
genome integrity that restrains nucleolytic degradation of damaged replication forks.34	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INTRODUCTION 35	  
Replication stress is any pathological process that compromises the fidelity of genome 36	  
duplication (Zeman and Cimprich, 2014). The Fanconi Anaemia (FA)/homologous recombination 37	  
(HR) pathway plays a central role in combatting replication stress (Gari and Constantinou, 2009). 38	  
FA is a rare chromosomal instability syndrome characterized by severe developmental 39	  
abnormalities, tumour predisposition and a hypersensitivity to agents that induce DNA inter-strand 40	  
cross-links (ICLs), such as mitomycin C (MMC) and cisplatin. To date, mutations in at least 16 41	  
different genes (FA complementation groups A-Q) have been identified in patients exhibiting 42	  
features consistent with FA (reviewed in Walden and Deans, 2014). 43	  
Whilst historically the FA/HR pathway has been associated with the HR-dependent repair 44	  
of ICLs, it plays a broader role in protecting cells from replication stress. Indeed, HR-deficient (and 45	  
some FA) cell lines are hypersensitive to replication stress-inducing agents that do not induce ICLs 46	  
(e.g. aphidicolin [APH] and hydroxyurea [HU]) (Howlett et al., 2005). It has been proposed that FA 47	  
and HR proteins function to: (i) protect stalled/collapsed forks from uncontrolled nucleolytic attack 48	  
(which may render such forks unrecoverable and/or prone to inappropriate repair) (Schlacher et 49	  
al., 2011; 2012); and (ii) in some cases may facilitate their restart once repair is complete. Cells 50	  
defective in these processes exhibit an increase in under-replicated DNA, particularly at common 51	  
fragile sites (CFS). This can result in the generation of ultra-fine anaphase bridges (UFBs), and 52	  
can ultimately manifest as chromosome breakage and micronuclei (Naim and Roselli, 2009a). The 53	  
accumulation of such genetic damage over time eventually triggers cell death, and may contribute 54	  
to the attrition of highly replicating cells, such as germ and haematopoietic cells (Garaycoechea 55	  
and Patel, 2014). 56	  
 Despite extensive research, it is still not completely understood how the cell regulates 57	  
repair of replication damage via the FA/HR pathway. A wide variety of DNA damage response 58	  
(DDR) and DNA repair proteins, including components of the FA/HR pathway, are recruited to 59	  
stalled forks upon replication stress (Sirbu et al., 2013). However, it is unclear how replication forks 60	  
requiring repair are marked: this might involve RPA coated ssDNA, specific DNA secondary 61	  
structures or damage-inducible post-translational modifications of the replication machinery and/or 62	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surrounding chromatin. It is also likely that some repair proteins are constitutive components of the 63	  
replication fork machinery, to allow immediate initiation of the DDR once a lesion is encountered. 64	  
 We have identified an uncharacterised factor, BOD1L, associated with newly replicated 65	  
chromatin. Cells lacking BOD1L accumulate catastrophic levels of genome damage following 66	  
replication stress, particularly after MMC exposure, manifesting as excessive chromosome 67	  
breakage. Although related to the mitotic regulator BOD1, we demonstrate that BOD1L does not 68	  
regulate spindle orientation but rather functions to protect stalled/damaged replication forks from 69	  
uncontrolled DNA2-dependent resection. We further show that BOD1L functions within the FA 70	  
pathway as part of the fork protection machinery, to stabilize Rad51 on chromatin by suppressing 71	  
the anti-recombinogenic and pro-resection activities of Fbh1 and BLM. Taken together, our data 72	  
establish that BOD1L is a critical factor associated with the replication machinery that acts to 73	  
promote fork stability by counteracting negative regulators of HR. 74	  75	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RESULTS 76	  
BOD1L is an uncharacterised factor that maintains genome stability following replication 77	  
stress 78	  
Isolation of proteins on nascent DNA (iPOND) is a robust method for the detection of 79	  
proteins at sites of newly replicated DNA (Sirbu et al., 2013). However, many proteins are sensitive 80	  
to the harsh conditions of iPOND. To overcome this issue, we first modified the original iPOND 81	  
protocol and subsequently utilised this new method coupled with mass spectrometry to identify 82	  
factors associated with nascent chromatin. As with other iPOND-based proteomic studies (Sirbu et 83	  
al., 2013), we identified numerous replication machinery components at ongoing forks, including 84	  
the MCM helicase, PCNA, the RFC complex, RPA and the replicative polymerases, polδ and polα 85	  
(Figure S1A). In addition to these proteins, we also identified Biorientation Defect 1-like (BOD1L); 86	  
a large, previously uncharacterised protein with N-terminal homology to the mitotic regulator BOD1 87	  
(Figure 1A) (Porter et al, 2007). Consistent with these data, we confirmed the presence of BOD1L 88	  
in EdU precipitates by Western blotting (Figure 1B). To verify that BOD1L associated with 89	  
replication fork proteins, we performed proximity-ligation assays with antibodies against PCNA and 90	  
BOD1L. We readily detected nuclear PLA signals in undamaged EdU-positive cells, which were 91	  
strongly reduced in EdU-negative and BOD1L-depleted cells (Figures 1C-D). Moreover, we could 92	  
co-immunoprecipitate BOD1L, and murine GFP-tagged Bod1L, with Mcm2 and Mcm7 (Figures 1E 93	  
and S1B). Together, these data indicate that BOD1L is localised at/near replication forks. 94	  
In addition to its homology to BOD1, the amino acid sequence of BOD1L also contains 95	  
several in vivo ATM/ATR phosphorylation sites (Matsuoka et al. (2007)), suggesting that BOD1L 96	  
might play a role in the DDR. To investigate this, we depleted cells of BOD1L using siRNA and 97	  
analysed cellular sensitivity to a range of DNA damaging agents. Knockdown of BOD1L exquisitely 98	  
hypersensitised cells to agents that induce replicative stress, in particular MMC (Figures 1F and 99	  
S1C), and was significantly more severe than loss of FANCA. However, co-depletion of FANCA 100	  
and BOD1L revealed that these two factors were epistatic for MMC hypersensitivity, suggesting 101	  
that BOD1L may function within the FA pathway. Treatment of BOD1L-depleted cells with 102	  
replication stress-inducing agents also induced increased micronuclei formation, indicating a 103	  
critical role for BOD1L in maintaining genome stability upon replication damage (Figure 1G). 104	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Importantly, these observations were recapitulated in several cell lines, and in two independent 105	  
DT40 BOD1L knockout clones (Figures S1D-H), demonstrating that the genome instability 106	  
observed is specifically due to loss of BOD1L, and is neither cell line nor organism specific. 107	  
 108	  
BOD1L and BOD1 are functionally distinct 109	  
BOD1 is a mitotic factor that associates with metaphase chromosomes and is essential for 110	  
correct orientation of the mitotic spindle (Porter et al, 2007; Porter et al, 2013). Given the sequence 111	  
similarity of the N-terminus of BOD1L to BOD1, it was conceivable that the increased micronuclei 112	  
observed in BOD1L-depleted cells arose from mitotic abnormalities. 113	  
To first investigate whether BOD1L was functionally related to BOD1, we performed 114	  
phenotypic analyses of cells depleted of either BOD1 or BOD1L by siRNA. Whilst loss of BOD1L 115	  
resulted in elevated DDR signalling, specifically the phosphorylation of H2AX and	   RPA2, this 116	  
defect was not observed in BOD1-depleted cells (Figure 2A). Furthermore, loss of BOD1 neither 117	  
increased MMC-induced micronuclei, nor engendered a cellular hypersensitivity to MMC or HU 118	  
(Figures 2B-D). In addition, unlike BOD1 depletion, loss of BOD1L did not cause mitotic or spindle 119	  
alignment defects (Figures 2E-F). Finally, immunostaining analyses of MMC-treated cells revealed 120	  
that BOD1L depletion increases the proportion of micronuclei that are acentric (CENPA-negative) 121	  
and that contain DNA double strand breaks (DSBs) (53BP1-positive), suggesting that these 122	  
micronuclei originated from unrepaired DNA damage (Figure 3A). Together, these observations 123	  
demonstrate that BOD1 and BOD1L perform separate roles in cell cycle regulation and genome 124	  
maintenance respectively. 125	  
 126	  
BOD1L functions within the Fanconi Anaemia pathway 127	  
 Micronuclei are observed in the absence of several genome stability factors, although FA-128	  
deficient are especially prone to ICL-induced micronucleation (Naim and Rosselli, 2009a). It has 129	  
been proposed that micronuclei arising in cells undergoing replication stress stem from a failure to 130	  
complete timely DNA replication. This results in the persistence of under-replicated DNA in cells as 131	  
they enter mitosis, which can manifest as UFBs, typically marked by PICH and flanked by 132	  
FANCD2 foci (Chan et al., 2007; Chan et al., 2009). These can lead to chromosome breakage and 133	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packaging of the damaged DNA into 53BP1 bodies visible in the subsequent G1 phase (Lukas et 134	  
al., 2011). 135	  
We next determined the prevalence of late replicating DNA, UFBs and G1-phase 53BP1 136	  
bodies in BOD1L deficient cells following MMC exposure. Loss of BOD1L dramatically increased 137	  
the percentage of mitotic cells positive for either FANCD2/PICH positive UFBs or for EdU foci 138	  
following MMC exposure (Figures 3B-D). Consistent with this, we observed a significant rise in the 139	  
number of 53BP1 G1 bodies in these cells, which was again more severe than depletion of FANCA 140	  
alone (Figures 3E-F). Collectively, these data suggest that the micronuclei observed in BOD1L-141	  
deficient cells are due to a	  failure to correctly resolve replication stress. 142	  
FA cells exhibit chromosomal hypersensitivity to agents that induce ICLs, caused in part by 143	  
the presence of under-replicated DNA, and exhibit chromatid breakage at specific loci, namely 144	  
CFS (Barlow et al., 2013; Durkin et al., 2007; Schoder et al., 2010). Strikingly, loss of BOD1L 145	  
resulted in catastrophic levels of chromosome breakage following MMC exposure, which was 146	  
markedly more severe than FANCA loss (Figures 3G and S2A). In agreement with previous data, 147	  
co-depletion of FANCA/BOD1L had no additional effect on genome instability. Furthermore, the 148	  
majority of BOD1L-deficient cells showed evidence of chromosome breakage at the CFS locus 149	  
FRA16D (Figure 3H). Importantly, genome stability in BOD1L-depleted cells was restored by the 150	  
stable expression of murine Bod1L, which is resistant to siRNA-mediated degradation, in two 151	  
independent HeLa cell clones (CFlap-mBod1L C1-4 and C5-20) (Figures S2B-D). Taken together, 152	  
these observations clearly demonstrate that BOD1L functions to resolve replication stress, in 153	  
conjunction with FA pathway components (Naim and Rosselli, 2009b). 154	  
Given that BOD1L is epistatic with a core FA pathway component, we evaluated the 155	  
functional integrity of this pathway in the absence of BOD1L. The DNA damage-induced mono-156	  
ubiquitylation of FANCD2 is a central event within the FA pathway, and is often used as a marker 157	  
of FA pathway integrity (Smogorzewska et al., 2007). Loss of BOD1L had no effect on the focal 158	  
recruitment of FANCD2 to sites of MMC damage, nor its ability to be mono-ubiquitylated (Figures 159	  
S2E-F), suggesting that BOD1L functions downstream of the FA core and FANCI/D2 complexes 160	  
within the FA/HR pathway.  161	  
 162	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BOD1L depletion compromises the fidelity of DNA replication following replication stress 163	  
The cellular response to replication stress is primarily coordinated by the ATR kinase, 164	  
which activates the intra-S phase checkpoint and protects stalled replication forks from collapse. 165	  
Recent studies on ATR-deficient cells have demonstrated that fork protection is crucial to maintain 166	  
CFS integrity (Koundrioukoff et al., 2013). Given that BOD1L-depleted cells exhibit CFS instability, 167	  
this suggests that BOD1L may protect replication forks directly, in a similar fashion to ATR. We 168	  
therefore hypothesised that loss of BOD1L would negatively impact S-phase regulation and/or 169	  
replication fork dynamics upon replication stress. 170	  
Initially, we sought to determine the effect of depleting BOD1L on cell cycle progression. 171	  
Compromising BOD1L expression had little effect on cell cycle progression in the absence of DNA 172	  
damage (Figure 4A). However, consistent with a defect in resolving S-phase damage, cells 173	  
lacking BOD1L rapidly accumulated in G2-phase following MMC exposure, with a concomitant 174	  
reduction in mitotic index (Figures 4B and S3A-B); a phenotype reminiscent of FA cells (Akkari et 175	  
al., 2001; Heinrich et al., 1998;). Next, to directly analyse the stability of on-going replication forks 176	  
following HU treatment, we quantified the symmetry of sister replication forks originating from the 177	  
same origin and travelling in opposite directions. Since sister forks typically display similar 178	  
replication rates (Conti et al., 2007), marked fork asymmetry indicates that individual forks are 179	  
more prone to stalling (Rodriguez-Lopez et al., 2002). Supportive of a role for BOD1L in promoting 180	  
fork stability, we observed a significant increase in replication fork asymmetry in BOD1L depleted 181	  
cells following HU treatment (Figure 4C), suggesting that damaged forks are slower to restart 182	  
and/or are more susceptible to stalling in its absence. 183	  
We also observed a significant increase in new origin firing in response to both HU and 184	  
MMC in cells lacking BOD1L, which was dependent on Cdk1/2 activity (Figures 4D-E and S3C-E). 185	  
However, this origin firing was not due to defective ATR/Chk1 signalling, since BOD1L-depleted 186	  
cells were proficient for Chk1 phosphorylation on both S317 and S345 in response to MMC 187	  
(Figure 4F). This phenotype was also not present in cells depleted of BOD1, further strengthening 188	  
the functional divergence of these proteins (Figure S3F). 189	  
Despite observing increased new origin firing and replication fork asymmetry in BOD1L 190	  
depleted cells after replication stress, there was no concomitant reduction in the number of 191	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restarted forks, nor any increase in fork stalling (first label terminations). One possible explanation 192	  
was that new origins were firing proximal to stalled/collapsed (red only labelled) forks in BOD1L 193	  
depleted cells, therefore artificially enhancing the quantification of restarted (red and green 194	  
labelled) replication forks. To investigate this, we used a Cdk1/2 inhibitor to inhibit new origin firing 195	  
in cells lacking BOD1L, and examined the impact on fork stalling/restart. Accordingly, we found 196	  
that inhibition of Cdk1/2 activity during HU exposure ablated new origin firing, increased the 197	  
prevalence of stalled replication forks, and decreased fork restart (Figure S3G), suggesting that 198	  
BOD1L prevents fork stalling upon replication stress. 199	  
Together, these data suggest that, upon the induction of replication stress, a lack of BOD1L 200	  
compromises fork stability and/or restart, which triggers dormant origin firing proximal to the 201	  
stalled/damaged fork.  202	  
 203	  
BOD1L protects stalled forks from uncontrolled resection 204	  
It is thought that uncontrolled origin firing in the absence of ATR leads to excessive ssDNA 205	  
generation and exhaustion of cellular pools of RPA, which both cause irreversible fork collapse 206	  
(Toledo et al., 2013). It is conceivable that global depletion of soluble RPA may also underlie the 207	  
excessive chromosome breakage observed in BOD1L deficient cells, since they also exhibit 208	  
increased origin firing, fork instability and defective fork restart. To investigate this, we first sought 209	  
to determine levels of ssDNA present in BOD1L-depleted cells following MMC exposure. Loss of 210	  
BOD1L resulted in a significant increase in RPA loading onto damaged chromatin compared to 211	  
control cells (Figures 5A-B and S4A). Moreover, ablation of BOD1L expression significantly 212	  
enhanced the formation of MMC-induced native BrdU foci (Figures 5C and S4B), consistent with 213	  
increased ssDNA generation in these cells. However, in contrast to ATR-deficient cells (Toledo et 214	  
al., 2013), RPA over-expression had no effect on either new origin firing or chromosomal instability 215	  
in the absence of BOD1L (Figures S4C-E). In addition, it is clear that the ATR-Chk1 pathway is 216	  
functional in BOD1L deficient cells (see Figure 4F). Therefore, although cells lacking ATR or 217	  
BOD1L display phenotypic similarities, it appears that the mechanisms underlying replication fork 218	  
stalling/collapse differ. 219	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It has been demonstrated that loss of FA pathway components such as BRCA2 and 220	  
FANCD2 leads to nucleolytic degradation of stalled replication forks, rendering them non-221	  
permissive for repair by HR (Schlacher et al., 2011; 2012). This excessive fork resection underlies 222	  
the increased chromosome breakage exhibited by BRCA2-null cells. The nucleases Mre11 and/or 223	  
DNA2 appear to perform this uncontrolled resection; inhibition of Mre11 can alleviate fork 224	  
degradation in BRCA2 deficient cells (Schlacher et al., 2011), and depletion of DNA2 rescues the 225	  
hypersensitivity of FANCD2 deficient cells to cisplatin (Karanja et al., 2014). To investigate whether 226	  
similar mechanisms underlie the phenotypes of BOD1L-deficient cells, we examined	   levels of 227	  
MMC-induced RPA2 phosphorylation on S4/S8, a well-established marker of DNA resection. 228	  
Depletion of BOD1L (but not BOD1) resulted in elevated levels of RPA2-S4/8 phosphorylation 229	  
following MMC treatment (Figures 5D-F and 2A), which could be restored to control levels by the 230	  
expression of CFlap-mBod1L (Figure S4F). Hyper-phosphorylation of RPA2 was also observed in 231	  
BOD1L-deficient cells following exposure to HU, indicating that this defect is not restricted to MMC-232	  
induced ICLs (Figure S4G). Therefore, these data suggest that BOD1L functions to suppress 233	  
resection. Consistent with this, we observed an increased localisation of BOD1L to damaged forks 234	  
undergoing resection (Figure 5G). 235	  
 To confirm that uncontrolled resection in BOD1L depleted cells occurs specifically at 236	  
replication forks, we used the approach described by Schlacher et al. (2011) to monitor 237	  
degradation of nascent DNA. In line with previous observations, loss of BRCA1 or BRCA2 238	  
increased the degradation of newly synthesized DNA at forks (apparent as a decreased IdU:CldU 239	  
ratio; Figure 6A and S5A-B). Interestingly, cells lacking BOD1L exhibited similar degradation of 240	  
stalled replication forks. Critically, this was epistatic with either BRCA1 or BRCA2 depletion, 241	  
suggesting that BOD1L and BRCA1/2 function within the same pathway to protect replication forks. 242	  
In support, BRCA2 and BOD1L co-depletion had no additional effect on cellular hypersensitivity to 243	  
MMC or RPA2 hyper-phosphorylation compared to loss of the individual genes alone (Figure S5C-244	  
E). Finally, BOD1L co-immunoprecipitated with the fork protection factors FANCD2 and BRCA2 245	  
(Figure 6B). Together, this provides strong evidence that BOD1L plays a vital role in preventing 246	  
unconstrained resection at stalled forks, in concert with FANCD2 and BRCA1/2. 247	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We next sought to ascertain whether the increased resection seen in cells devoid of 248	  
BOD1L was mediated by Mre11, DNA2 and/or Exo1; three nucleases implicated in fork resection. 249	  
In line with the study by Karanja et al. (2014), co-depletion of DNA2, but not Exo1, completely 250	  
repressed MMC-induced RPA2 S4/8 hyper-phosphorylation observed in cells lacking BOD1L 251	  
(Figures S5F-G). Furthermore, the over-resection of stalled forks was completely abolished by co-252	  
depletion of DNA2 with BOD1L. However, in contrast to previous findings with BRCA1/2 and 253	  
FANCD2 (Schlacher et al., 2011), inhibition of Mre11 by Mirin was unable to rescue nucleolytic fork 254	  
degradation in the absence of BOD1L (Figures 6C and S5H). Moreover, the combined loss of 255	  
DNA2 and BOD1L restored the MMC-induced micronuclei and chromosome damage to normal 256	  
levels (Figure 6D-E). This demonstrates that the severe genome instability in cells lacking BOD1L 257	  
arises from uncontrolled DNA2-dependent resection of damaged forks. 258	  
 259	  
BOD1L stabilises Rad51 at damaged replication forks by suppressing anti-recombinogenic 260	  
pathways 261	  
 The strand exchange protein Rad51 is best known as a principal effector of HR, but it also 262	  
plays a central role in stabilising/promoting the restart of damaged replication forks (Petermann et 263	  
al., 2010; Costanzo, 2011). Accordingly, the excessive fork degradation observed in BRCA2 or 264	  
FANCD2 deficient cells is restored by overexpressing an ATPase-dead Rad51 mutant, which 265	  
stabilises Rad51 nucleofilaments on ssDNA by preventing its ATP-dependent dissociation 266	  
(Schlacher et al., 2011; 2012). Thus, the loading of Rad51 onto stalled forks prevents uncontrolled 267	  
nucleolytic activity. 268	  
 To investigate whether a defect with Rad51 function underlies the excessive fork resection 269	  
observed in the absence of BOD1L, we exposed BOD1L-depleted cells to MMC, and then 270	  
monitored the accumulation/retention of Rad51 at sites of damage by immunofluorescence. 271	  
Notably, MMC-induced Rad51 foci formation was severely compromised in BOD1L-depleted cells 272	  
(Figure 6F). This was observed with 4 different BOD1L siRNA sequences, and was not due to any 273	  
alteration in Rad51 protein expression (Figures S5I-J). Moreover, the defective focal recruitment 274	  
of Rad51 (Figure S6A) upon damage could be restored by the expression of CFlap-mBod1L 275	  
(Figures S6B-C). In keeping, Rad51 also failed to load efficiently onto MMC-damaged chromatin 276	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in cells lacking BOD1L (Figure 6G). Consistent with this, BOD1L-depleted cells exhibited 277	  
increased numbers of MMC-induced radial chromosomes, and a concomitant decrease in the 278	  
frequency of MMC-induced SCEs (Figures S6D-E). Strikingly, the formation of IR-induced Rad51 279	  
foci at DSBs was unaffected in BOD1L-depleted cells (Figure S6F), suggesting that our 280	  
observations were not due to a global defect in Rad51 loading per se, but rather an inability to 281	  
localise/stabilise Rad51 to stalled replication forks. 282	  
Conceivably, a defect in recruiting Rad51 to stalled forks may be due to either a failure to 283	  
properly load Rad51 onto ssDNA, or an inability to maintain loaded Rad51 on chromatin. To 284	  
investigate the former possibility, we examined the impact of BOD1L depletion on the recruitment 285	  
of BRCA1, BRCA2 and PALB2, which are essential for Rad51 loading to ICLs (Bhattacharyya et 286	  
al., 2000; Godthelp et al., 2006; Xia et al., 2007). Cells lacking BOD1L exhibited no observable 287	  
defects in the re-localisation of BRCA1, BRCA2 or GFP-PALB2 to foci following exposure to MMC 288	  
(Figures 6H and S6G-I), suggesting that BOD1L may instead be required to stabilise/retain Rad51 289	  
on damaged chromatin.  290	  
Proteins involved in Rad51 filament dissolution play a vital role in controlling HR and 291	  
maintaining genome stability. Of these, the RecQ-like helicases BLM and RECQL5, and the F-box-292	  
containing helicase Fbh1 are the best studied: all three suppress Rad51-dependent HR, 293	  
particularly in response to replication stress. We speculated that the phenotypes observed in 294	  
BOD1L-deficient cells following MMC exposure may arise from the uncontrolled activity of one or 295	  
more of these anti-recombinase(s). We therefore siRNA-depleted BOD1L in combination with 296	  
BLM, Fbh1 or RECQL5, and monitored the levels of MMC-induced RPA S4/S8 phosphorylation 297	  
and Rad51 foci formation. Strikingly, loss of either Fbh1 or BLM (but not RECQL5) reduced MMC-298	  
induced RPA S4/S8 phosphorylation and restored Rad51 focus formation in BOD1L-depleted cells 299	  
(Figures 7A-B and S7A-C). Consistent with this, co-depletion of Fbh1 in BOD1L-depleted cells 300	  
restored MMC-induced loading of Rad51 onto chromatin (Figure S7D). However, depletion of 301	  
Fbh1 or BLM was unable to restore Rad51 focus formation in the absence of BRCA2, suggesting 302	  
that BOD1L acts downstream of BRCA2 to control Rad51 (Figure S7E). Depleting Fbh1 or BLM 303	  
expression also partially alleviated the over-resection of stalled replication forks observed in cells 304	  
lacking BOD1L, in keeping with the notion that Rad51 suppresses aberrant fork resection. 305	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Strikingly, RECQL5 depletion further increased fork resection in the absence of BOD1L, indicating 306	  
that these two factors act in separate pathways (Figures 7C and S7F). Lastly, ablating Fbh1 or 307	  
BLM expression also restored genome stability in cells depleted of BOD1L (Figures 7D and S7G). 308	  
Loss of RECQL5, however, had no restorative impact on MMC-induced chromosomal instability. 309	  
Finally, and in keeping with a role for BOD1L in stabilising Rad51 by counteracting BLM, both BLM 310	  
and Rad51 could be co-immunoprecipitated with BOD1L or CFlap-mBod1L (Figure 7E and S7H). 311	  
Taken together, these data demonstrate that BOD1L functions to restrain the pro-resection 312	  
and anti-recombinogenic functions of BLM/Fbh1 towards Rad51, thereby stabilising Rad51 on 313	  
chromatin and promoting HR-dependent repair of damaged replication forks. In the absence of 314	  
BOD1L, damaged replication forks undergo deleterious DNA2-dependent nucleolytic resection, 315	  
which compromises fork repair/restart and leads to catastrophic genome instability (Figure 7F).  316	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DISCUSSION 317	  
 The ability to efficiently resolve replication stress is vital to maintain genome stability. In this 318	  
study, we have identified BOD1L as a factor associated with newly replicated chromatin that 319	  
functions to prevent catastrophic DNA damage induced by replication stress by protecting 320	  
damaged replication forks from promiscuous nucleolytic degradation. 321	  
 322	  
Loss of Rad51-mediated fork protection underlies uncontrolled fork resection and genome 323	  
instability in BOD1L deficient cells 324	  
Rad51-dependent HR plays an essential role to stabilise, protect and promote the restart of 325	  
stalled or damaged replication forks. Central to this process is the BRCA1/BRCA2/PALB2-326	  
dependent loading of Rad51 onto RPA-coated ssDNA generated at such forks (Costanzo, 2011). 327	  
Rad51 fork loading stabilises replication fork intermediates and prevents deleterious nucleolytic 328	  
processing (Petermann et al., 2010; Schlacher et al., 2011; 2012). Loss of this protective activity 329	  
cripples the repair/restart of damaged forks and compromises genomic integrity. 330	  
We observed that BOD1L depleted cells exhibit increased fork degradation in a manner 331	  
comparable to BRCA1/BRCA2 deficient cells. This suggests that defects in the recruitment and/or 332	  
stabilisation of Rad51 allow degradation of damaged forks in BOD1L-deficient cells. Yet, in marked 333	  
contrast to the complete loss of BRCA2 or PALB2 (Yuan et al., 1999; Xia et al., 2006; Zhang et al., 334	  
2009), loss of BOD1L does not impact on the recruitment of Rad51 to DSBs induced by IR. This 335	  
implies that the function of BOD1L in regulating Rad51 in response to genotoxic damage is 336	  
restricted to lesions that cause replication stress. 337	  
 The repair and restart of forks requires the tightly regulated processing of replication 338	  
damage (such as ICLs) by several different nucleases. Whilst such nucleolytic processing is 339	  
important for cell survival, uncontrolled activity of these nucleases is also detrimental to genomic 340	  
integrity (Adamo et al., 2010; Karanja et al., 2014). In keeping with this, uncontrolled resection of 341	  
damaged forks and increased genomic instability observed in the absence of BOD1L was 342	  
completely alleviated by co-depletion of DNA2. In contrast, inhibition of Mre11 activity with Mirin 343	  
had no effect on the degradation of stalled replication forks in the absence of BOD1L. Since both 344	  
BRCA2 and FANCD2 suppress the activity of Mre11 at stalled forks (Schlacher et al., 2011; 2012; 345	  
15	  	  
Ying et al., 2012), our data suggests that BOD1L acts independently to inhibit aberrant DNA2 346	  
activity. Based on this, loss of BOD1L and BRCA2 should further increase fork resection, rather 347	  
than exhibit the epistatic relationship we observed. Although the underlying reason is unclear, we 348	  
postulate that nucleolytic degradation of a damaged fork by one nuclease prohibits further 349	  
processing by other nucleases. 350	  
Interestingly, since BOD1L co-immunoprecipitated with both BRCA2 and FANCD2 in 351	  
unperturbed cells, this raises two intriguing possibilities: that multiple fork protection factors act to 352	  
individually block the activities of different nucleases towards replication forks, and that they may 353	  
exist in a single complex. 354	  
 355	  
Mechanisms for BOD1L in stabilising Rad51 on damaged chromatin 356	  
 Our data demonstrates that loss of BOD1L is epistatic with deficiencies in BRCA1/BRCA2, 357	  
although the phenotypes observed in the absence of BOD1L cannot be explained by an inability to 358	  
recruit BRCA1, BRCA2 or PALB2 to sites of replication stress. Instead, co-depletion of BOD1L with 359	  
the anti-recombinogenic helicases Fbh1 or BLM restored Rad51 focal recruitment, stalled 360	  
replication fork resection and genome stability. Thus, chromatin-bound Rad51 may be more 361	  
susceptible to anti-recombinases, and/or Rad51 nucleofilaments may be more unstable, in the 362	  
absence of BOD1L. Importantly, Fbh1 or BLM knockdown failed to recover MMC-induced Rad51 363	  
foci formation in BRCA2-depleted cells, suggesting that BOD1L acts downstream of 364	  
BRCA2/PALB2 (see Figure S6F). Moreover, BOD1L associates with Rad51, suggesting that it 365	  
may stabilise Rad51 directly. Together, our data suggest that BRCA2 and BOD1L function 366	  
independently in a common pathway to protect replication forks, and that BOD1L acts in a similar 367	  
manner to the C-terminus of BRCA2 (Esashi et al., 2007; Schlacher et al., 2011), i.e. promoting 368	  
Rad51 nucleofilament stability. Intriguingly, co-depletion of BOD1L with another anti-369	  
recombinogenic helicase, RECQL5, failed to restore Rad51 foci formation, and actually 370	  
increased/accelerated fork degradation. This is in line with recent data demonstrating that the 371	  
combined loss of FA proteins with RECQL5 is additive in terms of fork degradation, and that BLM 372	  
and RECQL5 have divergent functions in the absence of an intact FA pathway (Kim et al., 2015).  373	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It is unclear why depletion of two independent factors (namely BLM or Fbh1) is able to 374	  
compensate for a lack of BOD1L, although BLM and Fbh1 have partially redundant functions in 375	  
DT40 cells (Kohzaki et al., 2007). Whilst Fbh1 and BLM both have pro- and anti-recombinogenic 376	  
activities (Bugreev et al., 2007; Fugger et al., 2009), BLM can displace Rad51 from ssDNA, and 377	  
can also potentiate HR through its ability to stimulate DNA2-dependent end-resection by binding to 378	  
RPA (Chen et al., 2013; Xue et al., 2013; Sturrzenegger et al., 2014). It is possible that loss of 379	  
BLM activity in BOD1L/BLM knockdown cells has two effects: (1) increases Rad51 filament 380	  
stability and; (2) compromises DNA2-dependent resection of damaged forks, the latter of which 381	  
causes the genome instability apparent in BOD1L deficient cells. 382	  
 Currently it is unknown whether BOD1L influences the activity of these anti-recombinases 383	  
directly or controls their access to the damaged replication fork and/or the Rad51 filament itself. 384	  
Given that BOD1L and BLM co-associate, it is tempting to speculate that BOD1L regulates BLM 385	  
activity directly. Alternatively, since the Rad51 paralogues stabilise Rad51 nucleofilaments by 386	  
blocking the translocase activities of anti-recombinogenic helicases (Amunugama et al., 2013; Liu 387	  
et al., 2011), BOD1L may act in an analogous fashion to regulate access of BLM/Fbh1 to Rad51, 388	  
ultimately stabilising Rad51 nucleofilaments at damaged replication forks. As a consequence, 389	  
ablating BOD1L could promote uncontrolled BLM-DNA2-dependent resection, and allow 390	  
BLM/Fbh1-dependent dissolution of Rad51 filaments. 391	  
 392	  
BOD1L functions in the latter stages of the FA/HR pathway 393	  
The phenotypic similarities between BOD1L-deficient cells and FA-defective cells, 394	  
particularly after ICL induction, suggest that BOD1L functions as part of the FA/HR pathway. 395	  
Indeed, loss of BOD1L and core/downstream FA components (namely FANCA and BRCA2) are 396	  
epistatic for MMC hypersensitivity and fork protection. In further support, the increased fork 397	  
resection apparent in both BOD1L-deficient and FANCD2-null cells is attributable to the nucleolytic 398	  
activity of DNA2 (Karanja et al., 2014). However, since BOD1L is not required for mono-399	  
ubiquitylation or relocalisation of FANCD2 to sites of DNA damage, and also that the chromatin 400	  
localisation/retention of Rad51 is unaffected in cells lacking FA core components or FANCD2/I 401	  
(Ohashi et al., 2005; Godthelp et al., 2006), this indicates that BOD1L functions in the latter stages 402	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of the FA pathway, downstream of FANCD2/I. This also suggests that fork protection mechanisms 403	  
independent of Rad51-loading (but perhaps dependent on Rad51 activity) also exist. 404	  
 405	  
Increased origin firing contributes to genome instability in BOD1L deficient cells 406	  
We have shown that cells depleted of BOD1L exhibit increased new origin firing following 407	  
the induction of replication stress. We hypothesise that this elevated origin firing is a cellular 408	  
response to an inability to complete DNA replication, caused by the uncontrolled resection of 409	  
stalled forks due to a failure to stabilise Rad51. This results in elevated levels of mitotic replication, 410	  
UFBs, G1 53BP1 bodies and severe chromosomal instability. 411	  
Whether Rad51 defects alone promote new origin firing is currently unclear. Increased new 412	  
origin firing does not occur in human cells depleted of Rad51 or in BRCA2-null CHO cells following 413	  
HU (Petermann et al., 2010; Jones et al., 2014), but increased new origin firing has been shown in 414	  
BLM-deficient cells and those lacking PALB2 (Davies et al., 2007; Nikkila et al., 2013). It therefore 415	  
remains to be determined whether the inability of BOD1L-depleted cells to retain Rad51 at stalled 416	  
replication forks contributes to the increase in origin firing. In spite of this, we predict that the 417	  
increased origin firing in BOD1L deficient cells could contribute to genome instability, perhaps due 418	  
to collisions between newly fired origins and damaged forks lying in close proximity. 419	  
 420	  
Summary 421	  
Taken together, our data leads us to propose the following model (Figure 7F): BOD1L 422	  
forms an essential component of the fork protection machinery. Upon stalling of a replication fork 423	  
(for example by an ICL), limited nucleolytic resection allows Rad51-dependent HR and 424	  
repair/restart of the stalled fork. BOD1L acts to stabilise Rad51 at such structures by protecting 425	  
Rad51 nucleofilaments from the activities of Fbh1/BLM. In the absence of BOD1L, Rad51 is 426	  
displaced from ssDNA by Fbh1/BLM, rendering the fork susceptible to uncontrolled resection by 427	  
DNA2, and leading to catastrophic genome instability, in part mediated by the presence of under-428	  
replicated DNA. 429	  430	  
18	  	  
EXPERIMENTAL PROCEDURES 431	  
 432	  
Cell culture and generation of cell lines 433	  
A549, HeLa, HeLa S3, H1299 and HeLa-FUCCI cells were grown in Dulbecco’s modified Eagle’s 434	  
medium supplemented with 10% fetal bovine serum (FBS) (Gibco) and penicillin/streptomycin. 435	  
HeLa-CFlap-BOD1L and U-2-OS SUPER-RPA cells were cultivated as above in the presence of 436	  
200 µg/ml Geneticin. U-2-OS and U-2-OS-PALB2-GFP cells were cultured in McCoys 5A medium, 437	  
supplemented with 10% FBS and penicillin/streptomycin. DT40 cells were cultured in RPMI 1640 438	  
medium (Invitrogen) supplemented with 7% FBS, 3% chicken serum, and 10 µM β-­‐439	  
mercaptoethanol. Further details of DT40s, HeLa-CFlap-mBOD1L cells, siRNA transfections and 440	  
clonogenic survival assays are given in the Extended Experimental Procedures. 441	  
 442	  
iPOND 443	  
iPOND was performed on HeLa S3 as described previously (Sirbu et al., 2013) with some 444	  
modifications to allow for improved detection of high molecular weight proteins, which are 445	  
described in Extended Experimental Procedures. In brief, newly synthesized DNA was labelled 446	  
with 10µM EdU, cells were fixed in 1% formaldehyde, permeablised and the Click reaction was 447	  
performed using Azide-PEG (3+3)-S-S-Biotin Conjugate (Click ChemistryTools). Following 448	  
sonication, EdU labelled DNA was precipitated using Streptavidin beads and eluted in buffer 449	  
containing DDT. 450	  
 451	  
Statistical analyses 452	  
Differences in survival assays were analysed by two-way ANOVA. Statistical differences in all 453	  
cases were determined by Student’s t-test, except for fork asymmetry, which was analysed by 454	  
Mann-Whitney rank sum test.  In all cases: NS = p>0.05; * = p<0.05; ** = p<0.01; *** = p<0.001.455	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FIGURE LEGENDS 669	  
Figure 1: BOD1L is present at newly-replicated DNA, and ensures cellular viability after 670	  
replication stress. (A) Upper: Schematic of human BOD1L and BOD1 domain structure and 671	  
ATM/ATR phosphorylation sites. Lower: Amino acid sequence alignment of BOD1L and BOD1. 672	  
Conserved residues (red) and similar residues (+) are denoted. (B) Immunoblotting of EdU-673	  
coprecipitates from HeLa S3 cells. (C-D) HeLa cells were transfected with the indicated siRNAs, 674	  
and	  pulsed with 10 µM EdU for 10 minutes before pre-extraction/fixation. EdU incorporation was 675	  
visualised with Click-iT chemistry, and detection of protein-protein associations were performed 676	  
using a fluorescently labelled PLA probe along with the indicated antibodies. (C) shows 677	  
quantification of PLA signals/nucleus from at least 100 cells (n = 3; lines denote mean values), and 678	  
representative images are shown (D). Scale bars = 10 µm. (E) HeLa nuclear cell extracts were 679	  
subjected to IP with the indicated antibodies, and inputs and immunoprecipitates were analyzed by 680	  
immunoblotting. Blots originate from a single gel. A white line denotes removal of irrelevant lanes. 681	  
(F) The survival of HeLa cells transfected with the indicated siRNA following exposure to 682	  
mitomycin C (MMC) or hydroxyurea (HU) was assessed by colony survival assay. (G) Micronuclei 683	  
formation following DNA damage was assessed in siRNA-transfected HeLa cells by fluorescence 684	  
microscopy. Plots (F)-(G) represent mean data from four independent experiments; error bars = 685	  
SEM. See also Figure S1. 686	  
 687	  
Figure 2: BOD1L is functionally distinct from BOD1. (A). Whole cell extracts (WCE) of HeLa 688	  
cells transfected with the indicated siRNA were analysed by immunoblotting after exposure to 50 689	  
ng/ml MMC for the denoted times.	  (B) HeLa cells from (A) were exposed to 50 ng/ml MMC for 24 690	  
h, and micronuclei enumerated.	   (C-D) The survival of HeLa cells transfected with the indicated 691	  
siRNA was assessed by colony survival assay as in Figure 1F. (E-F) Untreated HeLa cells from 692	  
(A) were immunostained with antibodies to α-tubulin and PCNT1, and the percentage of mitotic 693	  
cells in each stage of mitosis (E), or their ability to form centrosomes (F), was analysed by 694	  
immunofluorescence. Scale bars = 10 µm. Data represent mean ± SEM of three independent 695	  
experiments. 696	  
 697	  
28	  	  
Figure 3: BOD1L knockdown leads to problematic resolution of replication stress. (A)	  The 698	  
percentage of micronuclei positive for either 53BP1 or CENPA was quantified by 699	  
immunofluorescence microscopy in HeLa cells transfected with indicated siRNAs after exposure to 700	  
50 ng/ml MMC for 24 h. (B) The percentage of mitotic cells with PICH-positive UFBs was 701	  
quantified in transfected HeLa cells after exposure to 250 ng/ml MMC for 3 h and release into fresh 702	  
media for 36 h. (C) The mean percentage of PICH-positive UFBs with terminal FANCD2 foci in 703	  
mitotic cells from (B) is indicated. (D) Cells from (B) were pulsed with 10 µM EdU for 45 minutes 704	  
before fixation. Mitotic EdU incorporation was visualised with Click chemistry labelling, and the 705	  
mean number of EdU foci per mitotic cell, and merged representative images, are shown. Scale 706	  
bars = 10 µm. (E-F) HeLa-FUCCI cells were siRNA-transfected, and exposed to 50 ng/ml MMC for 707	  
24 h. (E) WCE were analysed by immunoblotting. Loading control denotes a non-specific protein 708	  
detected by anti-BOD1L antibody. (F) The number of 53BP1 bodies in RFP-positive (i.e. G1) cells 709	  
was enumerated. (G) Damage to metaphase chromosomes from HeLa cells subjected to the 710	  
indicated siRNAs was determined by Geimsa staining and light microscopy. Upper: Graphs 711	  
integrate data from three independent experiments (n = 150; lines denote mean values). Lower: 712	  
Representative metaphase spreads are shown, with chromosomal damage denoted by 713	  
arrowheads. (H) Cells from (G) were analysed by FISH using probes against FRA16D. Plots 714	  
represent mean ± SEM of three independent experiments. See also Figure S2. 715	  
 716	  
Figure 4: BOD1L knockdown increases origin firing after replication stress and destabilises 717	  
replication forks. (A-B) The cell cycle profiles of HeLa cells subjected to the indicated siRNAs 718	  
were analysed by flow cytometry. Representative profiles from untreated cells (A) or after exposure 719	  
to 250 ng/ml MMC for 3 h (B) are shown. (C-D) DNA fibre analysis of HeLa cells transfected with 720	  
the indicated siRNAs. Cells were pulsed with CldU, exposed to 2 mM HU for 2 h, and pulsed with 721	  
IdU. Plots indicate ratios of left/right fork lengths of bidirectional replication forks travelling from a 722	  
single origin. Lines denote median ratios (C). DNA fibres were enumerated, and the percentage of 723	  
new origins (IdU-labelled only) is displayed (D). (E) Transfected cells from (C) were exposed to 50 724	  
ng/ml MMC for 24 h, and pulsed sequentially with CldU and IdU. DNA fibres were quantified, and 725	  
the percentage of new origins is displayed. (F) WCE of HeLa cells transfected as above and 726	  
29	  	  
exposed to MMC for the indicated times were analysed by immunoblotting. *Chronic = 50 ng/ml 727	  
MMC. **Acute = 250 ng/ml MMC for 3h followed by wash out. Times for acute exposure indicate h 728	  
post washout. Plots represent mean ± SEM of at least three independent experiments. See also 729	  
Figure S3. 730	  
 731	  
Figure 5: BOD1L prevents excessive ssDNA formation and RPA2 hyper-phosphorylation 732	  
after MMC exposure. (A)	  Soluble and chromatin fractions of U-2-OS cells transfected with the 733	  
indicated siRNAs, and exposed to 100 ng/ml MMC for 24 h, were analysed by immunoblotting. 734	  
Loading control denotes a non-specific protein detected by anti-BOD1L antibody. Blots originate 735	  
from a single gel. A white line denotes removal of superfluous lanes. (B) RPA foci formation was 736	  
analysed in HeLa cells transfected as above and exposed to 50 ng/ml MMC for the denoted times. 737	  
(C) Native BrdU foci formation in U-2-OS cells by fluorescence microscopy. Cells were transfected 738	  
with the indicated siRNAs, and BrdU added for 24 h. Cells were exposed to 50 ng/ml MMC for a 739	  
further 24 h in the presence of BrdU, and immunostained with antibodies to BrdU and γH2AX. Foci 740	  
formation was analysed (see Figure S4B), and enumerated. (D) WCE of HeLa cells transfected as 741	  
in (B), and exposed to MMC for the indicated times, were analysed by immunoblotting. *Chronic = 742	  
50 ng/ml MMC. **Acute = 250 ng/ml MMC for 3h followed by wash out. Times for acute exposure 743	  
indicate h post washout. (E) Phospho-RPA (S4/S8) and RPA foci formation in transfected HeLa 744	  
cells exposed to 50 ng/ml MMC for 24 h. (F) The number of double positive cells from (E) was 745	  
enumerated. (G) Detection of protein-protein interactions was performed using a fluorescently 746	  
labelled PLA probe in HeLa cells from (B). The plot shows quantification of PLA signals/nucleus 747	  
from at least 100 cells (n=3;	   lines denote mean values), and representative images are shown. 748	  
Plots represent mean ± SEM of three independent experiments. Scale bars = 10 µm. See also 749	  
Figure S4. 750	  
 751	  
Figure 6: BOD1L is required to suppress aberrant fork resection after replication stress, and 752	  
is required for efficient Rad51 chromatin loading. (A) Fork degradation was analysed in U-2-753	  
OS cells. Cells were transfected with the indicated siRNAs, pulsed for 20 min each with CldU and 754	  
30	  	  
IdU, and exposed to 4 mM HU for 5 h. DNA was visualised with antibodies to CldU and IdU, and 755	  
plots denote the average ratios of IdU:CldU label lengths from three independent experiments. 756	  
Arrows indicate mean values (see Figure S5B). (B) HeLa nuclear cell extracts were subjected to 757	  
IP with the denoted antibodies, and inputs and immunoprecipitates were analyzed by 758	  
immunoblotting. Blots originate from a single gel. A white line denotes removal of irrelevant lanes. 759	  
(C) Fork degradation in U-2-OS cells transfected and treated as in (A) was analysed. Where 760	  
appropriate cells were treated with Mirin for the duration of the HU pulse (see Figure S5H). (D) 761	  
Micronuclei formation was quantified in HeLa cells transfected with the indicated siRNAs and 762	  
treated with 50 ng/ml MMC for 24 h. (E) Damage to metaphase chromosomes from cells (D) was 763	  
analysed (n = 150; lines denote mean values). (F) Rad51 foci formation was analysed in siRNA-764	  
transfected HeLa cells, and exposed to 50 ng/ml MMC for the indicated times. Scale bars = 10 µm. 765	  
(G) Soluble and chromatin fractions from Figure 5A were analysed by immunoblotting. (H) Foci 766	  
formation of BRCA1 and BRCA2 was analysed in HeLa cells from (F). Alternatively, U-2-OS-767	  
PALB2-GFP cells were transfected with the indicated siRNAs, exposed to 50 ng/ml MMC for 24 h, 768	  
and fixed. In both cases mean percentage of cells with foci are shown (see Figures S6G-I). Plots 769	  
(D-H) represent mean ± SEM of three independent experiments. See also Figures S5 and S6. 770	  
 771	  
Figure 7: BOD1L stabilises Rad51 chromatin loading to prevent excessive replication fork 772	  
resection. (A-B) RPA2/phospho-RPA2 S4/S8 (A) or Rad51 (B) foci formation was analysed in 773	  
HeLa cells transfected with the indicated siRNAs and exposed to 50 ng/ml MMC for 24 h. Scale 774	  
bars = 10 µm. (C) Fork degradation was assessed in U-2-OS cells transfected with the indicated 775	  
siRNAs as described in Figure 6A (see also Figure S7F). (D) Damage to metaphase 776	  
chromosomes in HeLa cells from (A) was analysed (n = 100; lines denote mean values). (E) HeLa 777	  
nuclear cell extracts subjected to IP with the indicated antibodies, and inputs and 778	  
immunoprecipitates were analyzed by immunoblotting. Blots originate from a single gel. A white 779	  
line denotes removal of irrelevant lanes. Plots (C-D) represent mean ± SEM of three independent 780	  
experiments. (F) Model of BOD1L function to promote Rad51 nucleofilament stability and prevent 781	  
uncontrolled resection of replication forks. Upon replication fork stalling, forks undergo minimal 782	  
nucleolytic processing (i), allowing Rad51 loading/protection by BRCA1/BRCA2/PALB2 (ii). BOD1L 783	  
31	  	  
acts to stabilise Rad51 nucleofilaments by protecting them from the activities of BLM/Fbh1 (iii), 784	  
thus preventing uncontrolled resection and allowing Rad51-mediated repair/restart of forks, 785	  
ultimately maintaining genome stability. In the absence of BOD1L, BLM/Fbh1 act to remove Rad51 786	  
from such forks exposing them to uncontrolled DNA2-dependent processing (iv). To compensate 787	  
for this fork instability, increased new origin firing occurs. When combined with uncontrolled 788	  
resection of replication forks, this leads to catastrophic genome instability (v). See also Figure S7. 789	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SUPPLEMENTAL FIGURE LEGENDS 1 
Figure S1: BOD1L ensures cellular viability and genome integrity after replication 2 
stress. Related to Figure 1. (A) Total peptides identified by mass spectroscopy analysis of 3 
EdU-coprecipitates isolated from HeLa S3 cells. A complete mass spectrometry data set is 4 
available on request to the Corresponding Author. (B) WCE from parental HeLa or HeLa-5 
CFlap-mBod1L cells (clone 5-20; see also Figure S2B) were subjected to IP with anti-GFP 6 
antibody, and inputs and recovered immunoprecipitates were analyzed by immunoblotting. 7 
Blots originate from a single gel. A white line denotes removal of irrelevant lanes. (C) HeLa 8 
cells were transfected with the indicated siRNA for 72 h and exposed to the indicated doses of 9 
UV-C or aphidicolin (APH), left to form colonies for 14 days, and then stained with methylene 10 
blue and counted. (D) U-2-OS and H1299 cells were transfected as in (C), exposed to 50 11 
ng/ml MMC for 24 h, and micronuclei formation was assessed by immunofluorescence. (E) 12 
PCR screening of WT and BOD1L-deleted (Δexon 1/Δexon 10) DT40 clones using the primers 13 
in (F). The presence of PCR products denotes successful recombination of the homology 14 
arms, and thus deletion of the desired region. (F) Schematic of the Gallus gallus BOD1L locus 15 
(upper) with targeting vectors spanning exons 1-5 and exon 10 (middle), and a schematic of 16 
the targeted Δexon 1/Δexon 10 locus (lower). Positions of screening primers are shown. (G) 17 
WT DT40s, and two clones lacking exons 1-5 and exon 10 of BOD1L, were exposed to the 18 
indicated doses of MMC, left to form colonies in soft agar, stained with methylene blue and 19 
counted. Plots represent mean data from four independent experiments; error bars represent 20 
SEM. Two-way ANOVA. (H) WT or BOD1L-deleted DT40s were exposed to 12.5 ng/ml MMC 21 
for 24 h, and micronuclei formation assessed by immunofluorescence. Plots represent mean 22 
data from three independent experiments; error bars represent SEM; Student’s t-test. * = 23 
p<0.05; *** = p<0.001. 24 
 25 
Figure S2: BOD1L knockdown increases genomic instability after replication stress. 26 
Related to Figure 3.  (A) HeLa, A549 and U-2-OS cells were treated as in Figure 3G, and 27 
damage to metaphase chromosomes was analysed by Geimsa staining and light microscopy. 28 
Graphs integrate data from 50 cells for each condition from three independent experiments. 29 
(B-D) Parental HeLa or HeLa-CFlap-mBod1L cells (clones C1-4 and C5-20) were transfected 30 
with the indicated siRNA for 72 h, and: (B) Whole cell extracts of cells (WCE) were analysed 31 
by immunoblotting; (C) Micronuclei formation was assessed by immunofluorescence; (D) 32 
Metaphase chromosomes were analysed by Geimsa staining and light microscopy. (E) HeLa 33 
cells from Figure 3A were immunostained with antibodies to FANCD2, and foci formation 34 
analysed by fluorescence microscopy.  Plot indicates quantification of cells with more than 10 35 
FANCD2 foci per cell from four independent experiments. (F) U-2-OS cells were transfected 36 
with the indicated siRNA for 72 h, exposed to 250 ng/ml MMC for 3 h, left to recover for the 37 
indicated times, and WCE were analysed by immunoblotting. Scale bars = 10 μm. NS = 38 
p>0.05; ** = p<0.01; Students’ t-test. 39 
 40 
Figure S3: The effect of BOD1L depletion on DNA replication kinetics. Related to Figure 41 
4.  (A) Quantification of cell cycle profiles shown in Figure 4B.  Data is representative of the 42 
mean ± SEM of four independent experiments. (B) Cells from (A) were immunostained with 43 
antibodies to phosphorylated histone H3-Ser10, and the percentage of mitotic cells determined 44 
by flow cytometry. Data represent mean ± SEM of four independent experiments. (C) DNA 45 
fibres from Figure 4E were quantified. The percentages of ongoing forks, first-label 46 
(bidirectional) origins, new origins (IdU-labelled only), first-label terminations (CldU-labelled 47 
only) and second label terminations are displayed. (D) HeLa cells were treated as in Figure 48 
4E except that, where indicated, they were treated with CDK1/2 inhibitor for 3 h prior to pulse 49 
labelling. Plot displays percentage of new origins (IdU-labelled only). (E) U-2-OS cells were 50 
transfected with the indicated siRNA for 72 h, and DNA fibres prepared as in Figure 4E. The 51 
percentage of new origins (IdU-labelled only) is displayed. (F) HeLa cells were transfected with 52 
the indicated siRNAs, and the DNA combed and analysed as above. (G) Cells were treated as 53 
in Figure 4D, except that, where indicated, they were treated with CDK1/2 inhibitor for the 54 
duration of HU exposure (2 h). Plots display average percentages of the relevant fork 55 
structure(s) from three independent experiments; error bars represent SEM. ** = p<0.01; 56 
Students’ t-test. 57 
 58 
Figure S4: BOD1L is necessary to prevent excessive ssDNA formation and RPA2 hyper-59 
phosphorylation after replication stress. Related to Figure 5.   (A) Foci formation in HeLa 60 
cells from Figure 5B was analysed by fluorescence microscopy, and fluorescence intensity 61 
per nucleus was quantified using ImageJ. Lines denote mean values from three independent 62 
experiments. (B) U-2-OS cells were treated as in Figure 5C, and immunostained with 63 
antibodies to BrdU and γH2AX. Representative images are shown. Scale bars = 10 μm. (C-E) 64 
Vector U-2-OS or SUPER-RPA U-2-OS cells were transfected with the indicated siRNAs and 65 
exposed to 50 ng/ml MMC for 24 h. (C) Left panel: WCE of the indicated cell lines were 66 
analysed by immunoblotting. Right panel: Transfected Vector or SUPER-RPA cells were 67 
treated as in Figure 4E, and the plots display the percentage of new origins (IdU-labelled 68 
only). (D) Damage to metaphase chromosomes was analysed by Geimsa staining and light 69 
microscopy. Graphs integrate data from 150 cells, in total, for each condition from three 70 
independent experiments, and are displayed as fold change compared to control siRNA-71 
transfected cells. (E) WCE of the indicated cell lines were analysed by immunoblotting. (F) 72 
Parental HeLa or HeLa-CFlap-mBod1L cells (clones C1-4 and C5-20) were transfected with 73 
the indicated siRNA for 72 h, exposed to 50 ng/ml MMC for 24 or 48 h, and WCE were 74 
analysed by immunoblotting. (G) HeLa cells were transfected with the indicated siRNA for 72 75 
h, exposed to 250 μM HU for 24 h, and harvested immediately (LI), or left to recover for a 76 
further 24 h (WO). WCE were analysed by immunoblotting.   77 
 78 
Figure S5: BOD1L is required to suppress aberrant end resection at replication forks 79 
after replication stress. Related to Figure 6.  (A) U-2-OS cells were transfected with the 80 
indicated siRNAs for 72 h, pulsed for 20 min each with CldU and IdU, and exposed to 4 mM 81 
HU for 5 h. DNA was visualised with antibodies to CldU and IdU, and replication fork length 82 
was calculated. Plots denote the average ratios of IdU:CldU label lengths from three 83 
independent experiments. Arrows indicate mean ratios. (Inset) WCE of cells were analysed by 84 
immunoblotting. Control siRNA panel is from the same gel as in Figure S7C. A white line 85 
denotes removal of irrelevant lanes. (B) Average values of IdU:CldU label lengths from DNA 86 
isolated from cells in Figures 6A and S6A is indicated, and SEM are denoted. (C) HeLa cells 87 
were transfected for 72 h with the indicated siRNAs, exposed to the indicated doses of MMC, 88 
left to form colonies for 14 days, and then stained with methylene blue and counted. Plots 89 
denote the average values from three independent experiments. (D) WCE of cells from (C) 90 
were analysed by immunoblotting. Loading control denotes a non-specific protein detected by 91 
anti-BOD1L antibody. (E) HeLa cells from (C) were exposed to 50 ng/ml MMC for 24 h, 92 
immunostained with antibodies to RPA2 and phospho-RPA S4/S8, and foci formation was 93 
analysed by fluorescence microscopy. The average percentage of double-positive cells is 94 
shown. (F) HeLa cells were transfected with the indicated siRNA for 72 h, exposed to 50 ng/ml 95 
MMC for 24 h, immunostained with antibodies to RPA2 and phospho-RPA S4/S8, and foci 96 
formation was analysed by fluorescence microscopy. The average percentage of double-97 
positive cells from three independent experiments is shown. (G) WCE of HeLa cells from (F) 98 
were analysed by immunoblotting. (H) DNA from U-2-OS cells in Figure 6C was visualised 99 
with antibodies to CldU and IdU, and replication fork length was calculated.  Average values 100 
and SEM are denoted. (I-J) HeLa cells were transfected with the indicated siRNAs, exposed to 101 
50 ng/ml MMC for 24 h, and either: RAD51 foci formation was analysed by fluorescence 102 
microscopy (I); or RAD51 expression was analysed by immunoblotting (J). siRNAs18-21 were 103 
individual siRNAs from the SMARTpool. 104 
 105 
Figure S6: BOD1L enables RAD51 chromatin loading to promote efficient homologous 106 
recombination. Related to Figure 6. (A) HeLa cells were transfected with the indicated 107 
siRNA for 72 h, exposed to 50 ng/ml MMC for 24 h, and immunostained with antibodies to 108 
RAD51. Foci formation was analysed by fluorescence microscopy, and quantified into three 109 
distinct phenotypes (representative images are shown in the lower panel). (B-C) Parental 110 
HeLa or HeLa-CFlap-mBod1L cells (clones C1-4 and C5-20) were transfected with the 111 
indicated siRNA for 72 h, exposed to 50 ng/ml MMC, and immunostained with antibodies to 112 
RAD51. (B) Foci formation was analysed by fluorescence microscopy and quantified. (C) 113 
Representative images are shown. (D) The incidence of radial chromosome formation was 114 
analysed from metaphase spreads prepared as described in Figure 3G. ** = p<0.01; Students’ 115 
t-test. (E) HeLa cells were transfected with the indicated siRNA for 24 h, labelled with BrdU for 116 
a further 24 h, and exposed to 25 ng/ml MMC for a further 24 h. Sister chromatid exchanges 117 
were quantified from at least 50 cells from three independent metaphase spreads. Line = 118 
mean number of SCEs/chromosome. Error bars = SEM. *** = p<0.001; Mann-Whitney ranked 119 
sum test. (F) HeLa cells were transfected with the indicated siRNA for 72 h, exposed to 5 Gy 120 
of γ-irradiation, and immunostained with antibodies to RAD51. Scale bars = 10 μm. (G-I) The 121 
prevalence of nuclear foci of BRCA1, BRCA2, and PALB2-GFP in HeLa or U-2-OS-PALB2-122 
GFP cells from Figure 6H. Foci formation was analysed by fluorescence microscopy, and 123 
representative images are shown.  124 
 125 
Figure S7: BOD1L acts to restrain anti-recombinase activity to stabilise RAD51 126 
chromatin loading and prevent excessive resection of replication forks. Related to 127 
Figure 7. (A-B) HeLa cells were treated as in Figure 7A/B, and RPA2/RPA2-PS4/8 foci 128 
formation (A) or RAD51 foci formation (B) was analysed by fluorescence microscopy. The 129 
average percentage of double-positive cells (A) or RAD51-positive cells (B) is shown. (C) 130 
WCE of cells from (A) were analysed by immunoblotting. (D) U-2-OS cells were transfected 131 
with the indicated siRNAs, exposed to 100 ng/ml MMC for 24 h, and then fractionated. Soluble 132 
and chromatin fractions were analysed by immunoblotting. Blots originate from a single gel. A 133 
white line denotes removal of irrelevant lanes. (E) HeLa cells were transfected with the 134 
indicated siRNA for 72 h, exposed to 50 ng/ml MMC for 24h, and immunostained with 135 
antibodies to RAD51. Scale bars = 10 μm. (F) U-2-OS cells were treated as in Figure 7C, and 136 
IdU:CldU ratios were calculated in the presence/absence of HU. Average values and SEM are 137 
denoted. (G) Micronuclei formation was assessed by immunofluorescence in HeLa cells from 138 
Figure 7A. (H) WCE from parental HeLa or HeLa-CFlap-mBod1L cells from Figure S1B were 139 
subjected to IP with anti-GFP antibody, and inputs and recovered immunoprecipitates were 140 
analyzed by immunoblotting. The upper panel is identical to that shown in Figure S1B. A white 141 
line denotes removal of irrelevant lanes.  142 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 143 
Cell lines 144 
A549, HeLa, HeLa S3, U-2-OS, and H1299 were sourced from the ATCC. U2OS-PALB2-GFP 145 
were obtained from F. Esashi. HeLa-FUCCI were obtained from RIKEN BRC. 146 
 147 
Drugs and inhibitors 148 
HU, Aphidicolin, and MMC were from Sigma Aldrich, and were used as indicated in the Figure 149 
Legends. Cdk1/2 inhibitor III was used at 25 μM (Merck). dNTP analogues BrdU, EdU, CldU 150 
and IdU were from Sigma Aldrich, and were used as indicated. Mirin (Calbiochem) was used 151 
at 50 μM. 152 
 153 
Generation of HeLa-CFlap-BOD1L cells. 154 
A BAC containing the full length Mus musculus BOD1L locus was obtained from BacPac 155 
Resources. This BAC was modified to insert a C-terminal Flap tag by Red/ET recombination 156 
following a modified protocol from Genebridges. To generate HeLa-CFlap-BOD1L cells, HeLa 157 
cells have been transfected with CFlap-Bod1L BAC using Lipofectamine 2000 (Invitrogen), 158 
then selected for 3 weeks with Geneticin and single cell-sorted by FACS following high level of 159 
GFP expression. Two clones (C1-4 and C5-20) were expanded and used for further 160 
experiments. 161 
 162 
Generation of BOD1L knock out DT40 cell lines. 163 
BOD1L knock out DT40 cell lines were generated using two disruption cassettes targeting 164 
exons 1-5 and targeting exon 10 of the chicken BOD1L locus.  The chicken BOD1L locus was 165 
identified by BLAST search using the human protein sequence against the ENSEMBL draft 166 
chicken genome sequence. An ENSEMBL predicted transcript encompassed the entire 167 
BOD1L gene.  From this sequence, two disruption cassettes targeting exons 1-5 and targeting 168 
exon 10 were designed.  PCR oligos used to amplify 5′ and 3′ arms of the first construct 169 
targeting exons 1-5 were 170 
GCGGCCGCGGTCTCGGATCCATGGAGCGACAATGATGACACAGATGG/ 171 
GGTGATATCGGCGGCAAGCTGGCTACAGCGTGTTAGGAGGGTTGAGTG and 172 
ATTATACGAACGGTACTCGATGATTTGAAGAGGAAAGTGAAGAAGAACCTGTG/ 173 
GGATCCGAGACCGCGGCCGCCCTATCTTACTCACCACCCCCAAGTCCTCA respectively.  174 
PCR oligos used to amplify 5′ and 3′ arms of the second construct targeting exon 10 were 175 
AATATAAAGCTTGCGGCCGCCAGCGTTGTCCAAAGGACATCTG/ 176 
GTCAAGCTTCTATTTGGCATCTGTGGCTTGGACTG and 177 
GTACTTGAGTAGCGTGTAATCAGTGCAAGTGCTGATG/ 178 
GGCAAGCTTATAGCAGGGTGGGTTGGAACTAGATG respectively.  Targeting constructs 179 
were generated by cloning the PCR products into the pSH vector containing either puromycin 180 
or hygromycin resistance.  Transfections and selection of targeted DT40 clones were carried 181 
out as described previously (Niedzwiedz et al., 2004). To confirm the appropriate disruptions 182 
of the GgBOD1L locus, genomic DNA was obtained and the following PCR oligos were used 183 
to screen the clones: ScrF1, TGCATCAGGGATGCACATTCTC; ScrR1, 184 
TAAGACTGCTGCTGACACCTTCAC; ScrF2, GCGGGACTATGGTTGCTGACTAATTGAG; 185 
ScrR2, ACTAGCTGCGTCCCAAAGAGTTTC; ScrF3, 186 
GCTGGCATGCTGGAATGTACTTTATGG; ScrR3, 187 
CTTCACAGAGGCGAGTAACTTCCTGTAAC; ScrF4, 188 
ACGATTCCGAAGCCCAACCTTTCATAG; ScrR4, ATCTTTGGAGATGTTCAAGGCCAGGTC 189 
(Figure S1E).   190 
 191 
siRNA Transfections 192 
siRNAs were from Dharmacon as SMARTpool (SP) or individual siRNAs deconvolved from the 193 
SMARTpool: BOD1L (SP, siRNA-18,-19,-20,-21); BOD1 (SP). SP and BOD1L siRNA-19 were 194 
used for all experiments unless stated. siRNA transfections were performed with siRNA 195 
duplexes (100 nM) using Oligofectamine (Invitrogen). Whenever siRNAs were combined, the 196 
total concentration was kept at 100 nM. A custom siRNA targeting lacZ 197 
(CGUACGCGGAAUACUUCGAdTdT) was used as a scrambled, non-targeting siRNA, and is 198 
abbreviated as “Control siRNA”, or “Con siRNA”. All experiments were performed 72 h post 199 
knockdown unless otherwise stated. 200 
 201 
Colony survival assays 202 
Colony survival assays using HeLa cells were carried out as described (Stewart et al., 2003).  203 
For colony survival assays with DT40 cells, MMC-treated cells were plated in methylcellulose 204 
after exposure to a range of concentrations of the drug. Viable colonies were scored after 2-3 205 
weeks. 206 
 207 
DNA combing 208 
DNA combing was carried out essentially as described previously (Petermann et al., 2010). 209 
HU (2 mM) or MMC (50 ng/ml) treatments were for 2 h or 24 h respectively. For resection 210 
experiments, cells were pulse-labelled with CldU and IdU for 20 min each before a 5 h 211 
exposure to 4 mM HU. For quantification of replication structures, at least 250 structures were 212 
counted per experiment. The lengths of red or green labelled tracts were measured using 213 
ImageJ (National Institutes of Health; http://rsbweb.nih.gov/ij/) and arbitrary length values were 214 
converted into micrometers using the scale bars created by the microscope. 215 
 216 
Chromatin fractionation 217 
Subcellular fractionations were performed in U-2-OS cells essentially as described in (Mendez 218 
and Stillman, 2000), except that chromatin fractions were washed once after isolation in 200 219 
mM NaCl, 3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, plus protease inhibitor cocktail, and re-220 
suspended in UTB. 221 
 222 
Metaphase spreads, SCEs and FISH 223 
Chromosomal aberrations and sister chromatid exchanges (SCEs) were scored in Giemsa 224 
stained metaphase spreads.  For chromosome aberrations, demecolcine (Sigma) was added 225 
3-4 h prior to harvesting at a final concentration of 0.2 µg/ml. Cells were harvested by 226 
trypsinisation, subjected to hypotonic shock for 1 hour at 37°C in 0.3 M sodium citrate and 227 
fixed in 3:1 methanol:acetic acid solution.  Cells were dropped onto acetic acid humidified 228 
slides, stained for 15 minutes in Giemsa-modified (Sigma) solution (5% v/v in H2O) and 229 
washed in water for 5 minutes. 230 
 231 
For SCEs, 10 µM BrdU (Sigma) was added to the medium for two complete cycles 232 
(approximately 48 hours) before collection and 25ng/ml MMC was added 24 h before 233 
collection.  0.2 µg/ml demecolcine was added 3 h prior to harvesting and metaphase spreads 234 
were obtained as described above. Before Giemsa staining, slides were incubated in Hoescht 235 
33258 solution (10 µg/ml) for 20 minutes, exposed to UV light (355 nm) for 1 hour and washed 236 
for 1 hour at 60°C in 20× SCC.  Cells were harvested as described above. 237 
 238 
Fragile site FISH was performed as previously described by (Le Tallec et al., 2011).  Probes 239 
for the common fragile sites FRA3B and FRA16D were made from BACs RP11-170K19 and  240 
RP11-281J9, respectively (Children’s Hospital Oakland Research Institute) and were labelled 241 
with Biotin-conjugated nucleotides using the BIOPRIME DNA Labelling System (Invitrogen) 242 
according to manufacturer’s protocol.  For dioxigenin incorporation, the BIOPRIME DNA 243 
Labelling System was used, but Dioxigenin-conjugated dNTPs (Roche) were used instead of 244 
biotin-conjugated dNTPs.  Probes were purified using Illustra Probequant G-50 micro columns 245 
(GE Healthcare). 246 
 247 
Flow cytometry 248 
Flow cytometry was carried out as described previously (Townsend et al., 2009). Briefly, HeLa 249 
cells were harvested, fixed in 70% ethanol at -20°C for at least 1 h, and permeabilised with 250 
0.25% Triton-X100 for 15 at 4°C. For immuno-detection of phospho-histone H3 (Ser10), cells 251 
were then incubated with primary antibody for 1 h, washed in 1% BSA, and counterstained 252 
with Alexa Fluor-488 goat anti-mouse IgG antibody. Cells were then washed twice with 1% 253 
BSA, and stained with 25 μg/ml propidium iodide containing 0.1 mg/ml RNase A. Cells were 254 
analysed using an Accuri flow cytometer (BDBiosciences) in conjunction with CFlowplus 255 
software. Data represents that obtained from at least 30,000 cells. 256 
 257 
Antibodies and Western blotting 258 
Whole cell extracts were obtained by sonication in UTB buffer (8 M Urea, 50 mM Tris, 150 mM 259 
β-mercaptoethanol, protease inhibitor cocktail (Roche)) and analysed by SDS-PAGE following 260 
standard procedures. The following antibodies were used: H2A, γ-H2AX, BRCA2, RPA2, 261 
RAD51 (Merck Millipore); MRE11, phospho-histone H3 Ser-10, phospho-CDK2 Tyr-15 (Cell 262 
Signalling); MCM7, CHK1, PCNA, CDK2, FANCD2, BRCA1, BRCA2 (Santa Cruz 263 
Biotechnology); RECQL5, FANCA, EXO1, phospho-RPA2 Ser-4/8, phospho-CHK1 Ser-317, 264 
phospho-CHK1 Ser-345, MLL1 (Bethyl); CENPA, DNA2, BOD1, PCNT-1 (Abcam), α-tubulin, 265 
FLAG (Sigma Aldrich); GFP (Roche); BrdU (CldU) (AbD Serotec); BrdU (IdU) (Becton 266 
Dickinson); MCM2 (BD Transduction); 53BP1 (G. S. Stewart); PICH (H. Yu). Affinity purified 267 
polyclonal anti-BOD1L antibodies were generated by immunising rabbits with a purified GST-268 
fusion protein spanning amino acids 1,900 to 2,501 of human BOD1L (Accession number:  269 
NP_683692.2) (Eurogentec). 270 
 271 
Immunoprecipitations 272 
HeLa nuclear cells extracts (Cilbiotech) were clarified by centrifugation at 44,000 x g, 273 
immunoprecipitated with 5 μg of anti-BOD1L antibody or IgG for 3 h at 4 °C. After further 274 
clarification, immune complexes were isolated using protein-A sepharose (GE Healthcare), 275 
and analysed by immunoblotting. 276 
 277 
iPOND 278 
EdU-labeled sample preparation:  Logarithmically growing HeLa S3 cells (1 x 106 per ml) were 279 
incubated with 10 mM EdU for 10 min.  Following EdU labelling, cells were fixed in 1 % 280 
formaldehyde, quenched by adding glycine to a final concentration of 0.125 M and washed in 281 
PBS three times.  Collected cell pellets were frozen at -80 °C and cells were permeabilised by 282 
resuspending in ice cold 0.25 % Triton-X/PBS at a concentration of 1-1.5 x 107 cells per ml 283 
and incubating on ice for 30 min.  Before the Click reaction, samples were washed once in 0.5 284 
% BSA/PBS and once in PBS.     285 
 286 
Click reaction:  Cells were incubated in Click reaction buffer for 1h at room temperature 287 
containing 10 µM azide-PEG(3+3)-S-S-biotin conjugate (Click ChemistryTools, cat. no AZ112-288 
25), 10 mM sodium ascorbate, and 1 mM copper (II) sulfate (CuSO4) in PBS.  The ‘no Click’ 289 
reaction contained DMSO instead of biotin-azide.  Following the Click reaction, cells were 290 
washed once in 0.5 % BSA/PBS and once in PBS.  Cells were resuspended in lysis buffer (50 291 
mM Tris–HCl pH 8.0, 1 % SDS) containing protease inhibitor cocktail (Roche) and sonicated 292 
using a Diagenode Bioruptor® Plus for 40 cycles (30 sec on/30 sec off).  Samples were 293 
centrifuged at 14,500 xg at 4°C for 30 min and the supernatant was diluted 1:3 with NTN buffer 294 
(100 mM NaCl, 20 mM Tris pH 7.4 and 0.05 % NP40) containing protease inhibitors.  An 295 
aliquot was taken as an input sample.   296 
 297 
Purification:  Streptavidin–agarose beads (Novagen) were washed three times in NTN buffer 298 
containing protease inhibitor cocktail.  200 µl of bead slurry was used per 1x 108 cells.  The 299 
streptavidin–agarose beads were resuspended 1:1 in NTN buffer containing protease 300 
inhibitors and added to the samples.  Samples were then incubated at 4 °C for 4 h in light 301 
exclusion.  Following binding, the beads were then washed 4x with 1 ml NTN buffer and 302 
protein-DNA complexes were eluted by incubating with 5mM DTT in NTN buffer.  Cross-links 303 
were reversed by incubated samples in SDS sample buffer at 95 °C for 12 min.  Proteins were 304 
resolved on SDS-PAGE and detected by immunoblotting, or mass-spectrometry analysis was 305 
performed on the eluates.  Mass spectrometry was carried out as described previously 306 
(Adelman et al., 2013). A complete mass spectrometry data set is available on request to the 307 
Corresponding Author. 308 
 309 
 310 
Microscopy and Image Analysis 311 
HeLa, H1299, U-2-OS, HeLa-FUCCI or A549 cells were grown on glass coverslips. DT40 cells 312 
were grown in suspension, and dropped onto poly-L-lysine coated coverslip for 15 min. Cells 313 
were washed with PBS twice before fixation. For α-tubulin, PCNT-1, PCNA, CENPA and 314 
53BP1 immuno-detection, cells were fixed with methanol at -20 °C for 10 minutes. For PICH, 315 
FANCD2 and EdU detection, and for 53BP1 immuno-detection in FUCCI cells, cells were fixed 316 
in 3.6% paraformaldehyde for 10 min at room temperature before permeabilisation with 317 
nuclear extraction buffer (10 mM PIPES, 20 mM NaCl, 3 mM MgCl2, 300 mM sucrose, 0.5% 318 
Triton X-100) for 10 minutes. For RAD51, γ-H2AX, BRCA2 and RPA immuno-detection, cells 319 
were pre-treated with nuclear extraction buffer for 5 minutes on ice, and fixed in 3.6% 320 
paraformaldehyde for 10 minutes at room temperature. For in situ detection of nascent DNA in 321 
mitotic and interphase cells the Click-iT DNA Alexa Fluor 495 Imaging Kit (Invitrogen) was 322 
used.  For ssDNA (BrdU) analyses, cells were pre-treated with nuclear extraction buffer for two 323 
5 consecutive minute incubations on ice, then fixed as above. After fixation, cells were washed 324 
with PBS three times and then blocked with ADB (Antibody Dilution Buffer; 5% FCS in PBS) 325 
for 1 h at 4°C. Cells were incubated with primary antibody (diluted in ADB) for 1 h at room 326 
temperature, washed with ADB and then counterstained with Alexa Fluor-488 goat anti-rabbit 327 
IgG, Alexa Fluor-594 goat anti-mouse IgG, Alexa Fluor-350 goat anti-rabbit IgG, or Alexa 328 
Fluor-555 donkey anti-rabbit IgG secondary antibodies (Molecular Probes) diluted in ADB, for 329 
1 h at room temperature. Cells were then washed twice with ADB and coverslips were 330 
mounted onto glass slides with Vectashield mounting agent containing 0.4 μg/ml DAPI 331 
(Vectashield). Fluorescence images were taken using a Nikon E600 Eclipse microscope 332 
equipped with a 60X oil lens, and images were acquired and analysed using Volocity Software 333 
v4.1 (Improvision). For ssDNA analyses, BrdU foci were enhanced using the ImageJ convolve 334 
function, and the number of nuclear foci/cell quantified. 335 
 336 
Proximity ligation assays 337 
For proximity ligation assays (PLA), cells were fixed/permeabilised as appropriate for the 338 
primary antibodies used, incubated in primary antibody, and in situ proximity ligation was 339 
performed using Duolink Detection Kit in combination with anti-Mouse PLUS and anti-Rabbit 340 
MINUS PLA Probes, according to the manufacturer’s instructions (Sigma Aldrich Duolink). 341 
Nuclear foci were imaged as above, and the number of nuclear foci/cell quantified using 342 
ImageJ.  343 
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